Skip to main content
SpringerLink
Log in

Antidepressant Drugs in Elderly

  • Chapter
  • First Online:
Melatonin, Neuroprotective Agents and Antidepressant Therapy

  • 1596 Accesses

Abstract

In our society, scientific advances and the improvement of the living conditions are causing a “demographic transition” with a significant increase in the number of elderly people. Antidepressant treatment in older depressed patients is efficacious, but differences in the effectiveness of different antidepressants have not been demonstrated. With ageing, a series of changes occur in the elderly that modify both the pharmacokinetics and pharmacodynamics of antidepressants and may influence the efficacy, tolerability and safety of treatment in the elderly. Individualized therapy for each elderly patient is needed to achieve acceptable risk–benefit ratio. ratiobebenefitratio.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gallagher P, Lang PO, Cherubini A, et al. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol. 2011;67:1175–88.

    Article  PubMed  Google Scholar 

  2. Álamo C, López-Muñoz F, García-García P. Treatment of depression in elderly: the challenge to success. Int J Clin Psychiatry Ment Health. 2014;2:77–88.

    Article  Google Scholar 

  3. Álamo C, López-Muñoz F, García-García P, García-Ramos S. Risk–benefit analysis of antidepressant drug treatment in the elderly. Psychogeriatrics. 2014;14:261–8.

    Article  PubMed  Google Scholar 

  4. Wiese BS. Geriatric depression: the use of antidepressants in the elderly. BC Med J. 2011;53:341–7.

    Google Scholar 

  5. Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle age: a systematic review of comparative studies. Am J Psychiatry. 2005;162:1588–601.

    Article  PubMed  Google Scholar 

  6. Cole MG, Bellavance F, Mansour A. Prognosis of depression in elderly community and primary care populations: a systematic review and meta-analysis. Am J Psychiatry. 1999;156:1182–9.

    CAS  PubMed  Google Scholar 

  7. Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging. 2009;26:381–94.

    Article  CAS  PubMed  Google Scholar 

  8. Álamo C, López-Muñoz F. New antidepressant drugs: beyond monoaminergic mechanisms. Curr Pharm Des. 2009;15:1559–62.

    Article  PubMed  Google Scholar 

  9. López-Muñoz F, Álamo C. Neurobioloy of monoaminergic neurotransmission and antidepressants. In: Srinivasan V, Brzezinski A, Oter S, Shillcutt SD, editors. Melatonin and melatonergic drugs in clinical practice. New Delhi: Springer International; 2014. p. 321–41.

    Chapter  Google Scholar 

  10. Zhang H, Etherington LA, Hafner AS, et al. Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule. Mol Psychiatry. 2013;18:471–84.

    Article  CAS  PubMed  Google Scholar 

  11. Invernizzi R, Pozzi L, Garattini S, Samanin R. Tianeptine increases the extracellular concentrations of dopamine in the nucleus accumbens by a serotonin-independent mechanism. Neuropharmacology. 1992;31:221–7.

    Article  CAS  PubMed  Google Scholar 

  12. Álamo C, López-Muñoz F, García-García P. Influencia de los antidepresivos en la salud física del paciente deprimido. In: Bobes J, Giner J, López F, Saiz-Ruiz J, Zamorano E, editors. Salud Física en el Paciente con Depresión. Madrid: Fundación Española de Psiquiatría y Salud Mental; 2012. p. 281–365.

    Google Scholar 

  13. Fangmann P, Assion H, Juckel G, et al. Half a century of antidepressant drugs on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics. J Clin Psychopharmacol. 2008;28:1–4.

    Article  PubMed  Google Scholar 

  14. Calati R, Signorelli MS, Balestri M, et al. Antidepressants in elderly: metaregression of double-blind, randomized clinical trials. J Affect Disord. 2013;147:1–8.

    Article  CAS  PubMed  Google Scholar 

  15. Álamo C. Polifarmacia y fragilidad. Interacciones, reacciones adversas medicamentosas y seguridad de los fármacos. En: Guía de Buena Práctica Clínica en Geriatría. Fragilidad y nutrición en el anciano. Madrid: Sociedad Española de Geriatría y Gerontología; 2014.

    Google Scholar 

  16. American Geriatrics Society. Beers criteria update expert panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616–31.

    Article  Google Scholar 

  17. Gerson SC, Plotkin DA, Jarvik LF. Antidepressant drug studies, 1964 to 1986: empirical evidence for aging patients. J Clin Psychopharmacol. 1988;8:311–22.

    Article  CAS  PubMed  Google Scholar 

  18. Cleare A, Pariante CM, Young AH, et al. Members of the Consensus Meeting. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015;29:459–525.

    Google Scholar 

  19. Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. Clin Ther. 2009;31:945–61.

    Article  CAS  PubMed  Google Scholar 

  20. Tedeschini E, Levkovitz Y, Iovieno N, et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72:1660–8.

    Article  CAS  PubMed  Google Scholar 

  21. Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord. 2012;141:103–15.

    Article  CAS  PubMed  Google Scholar 

  22. National Institute of Health and Clinical Excellence (NICE). Clinical Guideline 23. The management of depression in primary and secondary care. 2004.

    Google Scholar 

  23. Wilkinson P, Izmeth Z. Continuation and maintenance treatments for depression in older people. Cochrane Database Syst Rev. 2012;(11):CD006727. doi:10.1002/14651858.CD006727.pub2.

  24. Andreescu C, Reynolds CF. Depresión a una edad avanzada: tratamiento basado en la evidencia y nuevos caminos prometedores para la investigación y la práctica clínica. Psiquatr Biol. 2012;19:116–26.

    Google Scholar 

  25. Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother. 2014;15:2525–42.

    Article  CAS  PubMed  Google Scholar 

  26. Chua HC, Chan LL, Chee KS, et al. Ministry of health clinical practice. Guidelines: depression. Singap Med J. 2012;53:137–44.

    CAS  Google Scholar 

  27. Álamo C, López-Muñoz F, Guerra JA. Psicofarmacología en Neuropsicogeriatría. In: Gil Gregorio P, editor. Tratado de Neuropsicogeriatría. Madrid: Ergon; 2010. p. 27–58.

    Google Scholar 

  28. Tan RS. Dose of tricyclic antidepressants in elderly patients. JAMA. 1999;281:1891–2.

    Article  CAS  PubMed  Google Scholar 

  29. Volz HP, Gleiter CH. Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998;13:341–55.

    Article  CAS  PubMed  Google Scholar 

  30. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62:792–8.

    Article  CAS  PubMed  Google Scholar 

  31. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry. 2003;64:5–12.

    Article  CAS  PubMed  Google Scholar 

  32. Lichtman JH, Bigger Jr JT, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American heart association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research: endorsed by the American psychiatric association. Circulation. 2008;118:1768–75.

    Article  PubMed  Google Scholar 

  33. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108:2–8.

    Article  CAS  PubMed  Google Scholar 

  34. Blanchette CM, Simoni-Wastila L, Zuckerman IH, Stuart B. A secondary analysis of a duration response association between selective serotonin reuptake inhibitor use and the risk of acute myocardial infarction in the aging population. Ann Epidemiol. 2008;18:316–21.

    Article  PubMed  Google Scholar 

  35. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894–8.

    Article  CAS  PubMed  Google Scholar 

  37. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108:32–6.

    Article  CAS  PubMed  Google Scholar 

  38. Undela K, Parthasarathi G, John SS. Impact of antidepressants use on risk of myocardial infarction: a systematic review and meta-analysis. Indian J Pharmacol. 2015;47:256–62.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005;91:465–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. National Collaborating Centre for Mental Health, commissioned by NICE. Depression in adults with a chronic physical health problem: treatment and management. National Clinical Practice Guideline 91. 2009.

    Google Scholar 

  41. National Health Service. UK Medicines Information. What is the antidepressant of choice in coronary heart disease? UKMi Q&A 55.6, 2012.

    Google Scholar 

  42. Van der Kooy K, van Hout H, Marwijk H, et al. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int J Geriatr Psychiatry. 2007;22:613–26.

    Article  PubMed  Google Scholar 

  43. Hackett ML, Anderson CS, House AO. Management of depression after stroke. A systematic review of pharmacological therapies. Stroke. 2005;36:1092–7.

    Article  CAS  Google Scholar 

  44. Chen Y, Guo JJ. Meta-analysis of antidepressant treatment for patients with poststroke depression. Stroke. 2006;37:1365–6.

    Article  PubMed  Google Scholar 

  45. Chen Y, Guo JJ, Zhan S, Patel NC. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother. 2006;40:2115–22.

    Article  CAS  PubMed  Google Scholar 

  46. Chen Y, Patel NC, Guo JJ, Zhan S. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007;22:159–66.

    Article  PubMed  Google Scholar 

  47. Chen Y, Guo JJ, Li H, et al. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case-control study. Ann Pharmacother. 2008;42:177–84.

    Article  PubMed  Google Scholar 

  48. Wu CS, Wang SC, Cheng YC, Gau SS. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry. 2011;168:511–21.

    Article  PubMed  Google Scholar 

  49. Péquignot R, Tzourio C, Péres K, et al. Depressive symptoms, antidepressants and disability and future coronary heart disease and stroke events in older adults: the Three City Study. Eur J Epidemiol. 2013;28:249–56.

    Article  CAS  PubMed  Google Scholar 

  50. Pan A, Sun Q, Okereke OI, et al. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA. 2011;306:1241–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Trifiro G, Dieleman J, Sen EF, et al. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. J Clin Psychopharmacol. 2010;30:252–8.

    Article  CAS  PubMed  Google Scholar 

  52. Lee YC, Lin CH, Lin MS, et al. Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study. J Clin Psychopharmacol. 2013;33:782–9.

    Article  CAS  PubMed  Google Scholar 

  53. Juang HT, Chen PC, Chien KL. Using antidepressants and the risk of stroke recurrence: report from a national representative cohort study. BMC Neurol. 2015;15:86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Wang MT, Chu CL, Yeh CB, et al. Antidepressant use and risk of recurrent stroke: a population-based nested case-control study. J Clin Psychiatry. 2015;76:e877–85.

    Article  PubMed  Google Scholar 

  55. Kharofa J, Sekar P, Haverbusch M, et al. Selective serotonin Reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007;38:3049–51.

    Article  CAS  PubMed  Google Scholar 

  56. Douglas I, Smeeth L, Irvine D. The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study. Br J Clin Pharmacol. 2011;71:116–20.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Aarts N, Akoudad S, Noordam R, et al. Inhibition of serotonin reuptake by antidepressants and cerebral microbleeds in the general population. Stroke. 2014;45:1951–7.

    Article  CAS  PubMed  Google Scholar 

  58. Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012;79:1862–5.

    Article  CAS  PubMed  Google Scholar 

  59. Mikami K, Jorge RE, Adams HP, et al. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry. 2011;19:1007–15.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Chollet F, Tardy J, Albucher J-F, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10:123–30.

    Article  CAS  PubMed  Google Scholar 

  61. Mead GE, Hsieh C-F, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012;11:CD009286.

    PubMed  Google Scholar 

  62. Mead G, Hackett ML, Lundström E, et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. Trials. 2015;16:369.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Mago R, Tripathi N, Andrade C. Cardiovascular adverse effects of newer antidepressants. Expert Rev Neurother. 2014;14:539–51.

    Article  CAS  PubMed  Google Scholar 

  64. Davies EA, O’Mahonny MS. Adverse drug reactions in special populations – the elderly. Br J Clin Pharmacol. 2015;80:796–807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Mitchell J, Trangle M, Degnan B, et al. Health care guideline: adult depression in primary care guideline [Internet]. Bloomington: Institute for Clinical Systems Improvement; 2013. Available at: https://www.icsi.org/_asset/fnhdm3/Depr.pdf.

    Google Scholar 

  66. Licht CM, De Geus EJ, Seldenrijk A, et al. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension. 2009;53:631–8.

    Article  CAS  PubMed  Google Scholar 

  67. Derby MA, Zhang L, Chappell JC, et al. The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol. 2007;49:384–93.

    Article  CAS  PubMed  Google Scholar 

  68. Mclntyre RS, Park Y, Law CW, et al. The association between conventional antidepressants and the metabolic syndrome a review of the evidence and clinical implications. CNS Drugs. 2010;24:741–63.

    Article  Google Scholar 

  69. Van der Kooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry. 2002;47:174–80.

    Google Scholar 

  70. Martín-Agueda B, López-Muñoz F, Rubio G, et al. Management of depression in primary care: a survey of general practitioners in Spain. Gen Hosp Psychiatr. 2005;27:305–12.

    Article  Google Scholar 

  71. Magnuson T, Keller BK. Treatment for geriatric depression. The Nebraska Geriatrics Education Center, 2009. Available at: http://app1.unmc.edu/intmed/geriatrics/index.cfm?conref=104.

  72. Fanoe S, Kristensen D, Fink-Jensen A, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. Eur Heart J. 2014;35:1306–15.

    Article  PubMed  Google Scholar 

  73. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004;45:371–7.

    Article  CAS  PubMed  Google Scholar 

  74. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Thase ME, Larsen KG, Reines E, et al. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23:1391–400.

    Article  CAS  PubMed  Google Scholar 

  76. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–9.

    Article  PubMed  Google Scholar 

  77. Pan A, Sun Q, Okereke OI, et al. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia. 2012;55:63–72.

    Article  CAS  PubMed  Google Scholar 

  78. Ludman EJ, Katon W, Russo J, et al. Depression and diabetes symptom burden. Gen Hosp Psychiatry. 2004;26:430–6.

    Article  PubMed  Google Scholar 

  79. Azevedo Da Silva M, Dugravot A, Balkau B, et al. D.E.S.I.R. Study Group. Antidepressant medication use and trajectories of fasting plasma glucose, glycated haemoglobin, β-cell function and insulin sensitivity: a 9-year longitudinal study of the D.E.S.I.R. cohort. Int J Epidemiol 2015. pii: dyv153.

    Google Scholar 

  80. Kivimäki M, Hamer M, Batty GD, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care. 2010;33:2611–6.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Khoza S, Barner JC, Bohman TM, et al. Use of antidepressant agents and the risk of type 2 diabetes. Eur J Clin Pharmacol. 2012;68:1295–302.

    Article  CAS  PubMed  Google Scholar 

  82. Derijks HJ, Meyboom RH, Heerdink ER, et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol. 2008;64:531–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Boyer P, Montgomery S, Lepóla U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo controlled trial. Int Clin Psychopharmacol. 2008;23:243–53.

    Article  PubMed  Google Scholar 

  84. Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med. 2007;8:503–13.

    Article  PubMed  Google Scholar 

  85. Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care. 2006;29:170–1.

    Article  PubMed  Google Scholar 

  86. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591–8.

    Article  PubMed  Google Scholar 

  87. Markowitz S, Gonzalez JS, Wilkinson JL, Safren SA. Treating depression in diabetes emerging findings. Psychosomatics. 2011;52:1–18.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Van Reedt Dortland AK, Giltay EJ, van Veen T, et al. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand. 2010;122:30–9.

    Article  CAS  PubMed  Google Scholar 

  89. Mclntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Exp Opin Drug Saf. 2006;5:523–37.

    Article  Google Scholar 

  90. Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry. 2003;64:883–9.

    Article  CAS  PubMed  Google Scholar 

  91. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs. placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62:190–8.

    Article  CAS  PubMed  Google Scholar 

  92. Le Melledo JM, Mailo K, Lara N, et al. Paroxetine-induced increase in LDL cholesterol levels. J Psychopharmacol. 2009;23:826–30.

    Article  PubMed  Google Scholar 

  93. Bostwick JM. A generalist’s guide to treating patients with depression. With an emphasis on using side effects to tailor antidepressant therapy. Mayo Clin Proc. 2010;85:538–50.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Fava M. Weight gain and antidepressants. J Clin Psychiatr. 2000;61 Suppl 11:37–41.

    CAS  Google Scholar 

  95. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry. 2001;62:256–60.

    Article  CAS  PubMed  Google Scholar 

  96. Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther. 2002;24:662–72.

    Article  CAS  PubMed  Google Scholar 

  97. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs. 2010;24:479–99.

    Article  CAS  PubMed  Google Scholar 

  98. Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. Maturitas. 2013;76:357–63.

    Article  CAS  PubMed  Google Scholar 

  99. Spigset O, Hedenmalm K. Hyponatraemia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by psychotropic drugs. Drug Saf. 1995;12:209–25.

    Article  CAS  PubMed  Google Scholar 

  100. Niranjan K, Nasim A. Hyponatraemia: removing the risk in the elderly. Geriatr Med. 2005;35:17–21.

    Google Scholar 

  101. Bouman WP, Pinner G, Johnson H. Incidence of selective serotonin-reuptake inhibitor (SSRI)-induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry. 1998;13:12–5.

    Article  CAS  PubMed  Google Scholar 

  102. Ayus JC, Arrief AI. Chronic hyponatremic encephalopathy in postmenopausal women. JAMA. 1999;281:2299–304.

    Article  CAS  PubMed  Google Scholar 

  103. Sultana J, Spina E, Trifirò G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol. 2015;11:883–92.

    Article  CAS  PubMed  Google Scholar 

  104. De Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake-inhibitors and upper gastrointestinal bleeding: population-based, case–control study. BMJ. 1999;319:1106–9.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323:655–8.

    Article  PubMed  PubMed Central  Google Scholar 

  106. De Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. 2011;28:345–67.

    Article  PubMed  Google Scholar 

  107. Ghio L, Puppo S, Presta A. Venlafaxine and risk of upper gastrointestinal bleeding in elderly depression. Curr Drug Saf. 2012;7:389–90.

    Article  PubMed  Google Scholar 

  108. Shin JY, Park MJ, Lee SH, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ. 2015;351:h3517.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Barbui C, Andretta M, De Vitis G, et al. Antidepressant drug prescription and risk of abnormal bleeding: a case-control study. J Clin Psychopharmacol. 2009;29:33–8.

    Article  PubMed  Google Scholar 

  110. Mahdanian AA, Rej S, Bacon SL, et al. Serotonergic antidepressants and perioperative bleeding risk: a systematic review. Expert Opin Drug Saf. 2014;13:695–704.

    CAS  PubMed  Google Scholar 

  111. Aloumanis K, Mavroudis K. The “depressive” face of osteoporosis and the “osteoporotic” face of depression. Hormones (Athens). 2013;12:350–62.

    Google Scholar 

  112. Bruyère O, Reginster JY. Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine. 2015;48:65–8.

    Article  CAS  PubMed  Google Scholar 

  113. Cizza G, Primma S, Coyle M, Gourgiotis L, Csako G. Depression and osteoporosis: a research synthesis with meta-analysis. Horm Metab Res. 2010;42:467–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. Bone. 2012;51:606–13.

    Article  CAS  PubMed  Google Scholar 

  115. Sansone RA, Sansone LA. SSRIs: bad to the bone? Innov Clin Neurosci. 2012;9:42–7.

    Google Scholar 

  116. Verdel BM, Souverein PC, Egberts TC, et al. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone. 2010;47:604–9.

    Article  CAS  PubMed  Google Scholar 

  117. Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos Int. 2013;24:121–37.

    Article  CAS  PubMed  Google Scholar 

  118. Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos Int. 2014;25:1473–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Reichenpfader U, Gartlehner G, Morgan LC, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf. 2014;37:19–31.

    Article  CAS  PubMed  Google Scholar 

  120. Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol. 2010;24:111–20.

    Article  CAS  PubMed  Google Scholar 

  121. Pae CU. Agomelatine: a new option for treatment of depression? Exp Opin Pharmacother. 2014;15:443–7.

    Article  CAS  Google Scholar 

  122. Schweitzer I, Maguire K. Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry. 2009;43:795–808.

    Article  PubMed  Google Scholar 

  123. Schulz R, Drayer RA, Rollman BL. Depression as a risk factor for non-suicide mortality in the elderly. Biol Psychiatry. 2002;52:205–25.

    Article  PubMed  Google Scholar 

  124. Bogner HR, Morales KH, Reynolds CF, et al. Course of depression and mortality among older primary care patients. Am J Geriatr Psychiatry. 2012;20:895–903.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Gallo JJ, Morales KH, Bogner HR, et al. Long term effect of depression care management on mortality in older adults: follow-up of cluster randomized clinical trial in primary care. BMJ. 2013;346:f2570.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Gallo JJ, Hwang S, Joo JH, et al. Multimorbidity, depression, and mortality in primary care: randomized clinical trial of an evidence-based depression care management program on mortality risk. J Gen Intern Med. 2016;31:380–6.

    Article  PubMed  Google Scholar 

  127. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–74.

    Article  PubMed  Google Scholar 

  128. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42:277–85.

    Article  CAS  PubMed  Google Scholar 

  129. Bremner JD, Wingard P, Walshe TA. Safety of mirtazapine in overdose. J Clin Psychiatry. 1998;59:233–5.

    Article  CAS  PubMed  Google Scholar 

  130. Crumpacker DW. Suicidality and antidepressants in the elderly. Proc Bayl Univ Med Cent. 2008;21:373–7.

    PubMed  PubMed Central  Google Scholar 

  131. Gusmão R, Quintão S, McDaid D, et al. Antidepressant utilization and suicide in Europe: an ecological multi-national study. PLoS ONE. 2013;8:e66455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Leon AC, Solomon DA, Li C, et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry. 2011;72:580–6.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Barak Y, Olmer A, Aizenberg D. Antidepressants reduce the risk of suicide among elderly depressed patients. Neuropsychopharmacology. 2006;31:178–81.

    CAS  PubMed  Google Scholar 

  134. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.

    Article  PubMed  PubMed Central  Google Scholar 

  135. Frank C. Pharmacologic treatment of depression in the elderly. Can Fam Physician. 2014;60:121–6.

    PubMed  PubMed Central  Google Scholar 

  136. Urban M, Navratil T, Pelclova D. Trends in CNS affecting drugs in the calls to t the Toxicological Information Center from 1997 to 2012. Neuro Endocrinol Lett. 2013;34:S25–30.

    Google Scholar 

  137. Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30:1206–27.

    Article  CAS  PubMed  Google Scholar 

  138. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences (Pharmacology Area), Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Madrid, Spain

    Cecilio Álamo & Pilar García-García

  2. Faculty of Health Sciences, Camilo José Cela University, Villanueva de la Cañada, Madrid, Spain

    Francisco López-Muñoz

  3. Neuropsychopharmacology Unit, Hospital 12 de Octubre Research Institute (i+12), Madrid, Spain

    Francisco López-Muñoz

  4. Portucalense Institute of Neuropsychology and Cognitive and Behavioural Neurosciences, Portucalense University, Porto, Portugal

    Francisco López-Muñoz

Authors
  1. Cecilio Álamo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisco López-Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pilar García-García
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francisco López-Muñoz .

Editor information

Editors and Affiliations

  1. Vice-Rectorate for Research and Sci, Camilo José Cela University Vice-Rectorate for Research and Sci, Madrid, Spain

    Francisco López-Muñoz

  2. International Medical Sciences Research Study Center, Sri Sathya Sai Medical Educational & Research Foundation, Coimbatore, India

    Venkataramanujam Srinivasan

  3. Department of Neurosciences and Ima, University of Chieti Department of Neurosciences and Ima, Italy, Italy

    Domenico de Berardis

  4. Department of Biomedical Sciences (Pharmacology Area), University of Alcalá, Madrid, Spain

    Cecilio Álamo

  5. Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan

    Takahiro A. Kato

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer India

About this chapter

Cite this chapter

Álamo, C., López-Muñoz, F., García-García, P. (2016). Antidepressant Drugs in Elderly. In: López-Muñoz, F., Srinivasan, V., de Berardis, D., Álamo, C., Kato, T. (eds) Melatonin, Neuroprotective Agents and Antidepressant Therapy. Springer, New Delhi. https://doi.org/10.1007/978-81-322-2803-5_29

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-2803-5_29

  • Published:

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-2801-1

  • Online ISBN: 978-81-322-2803-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation